An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)

Trial Profile

An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs A001-MeiraGTx (Primary)
  • Indications Retinal dystrophies
  • Focus Adverse reactions
  • Acronyms OPTIRPE65
  • Most Recent Events

    • 07 Dec 2017 According to a MeiraGTx media release, in November 2017, the first paediatric patient was treated at the Moorfields Eye Hospital in London.
    • 17 Oct 2017 According to a MeiraGTx media release, dosing has been completed in all 3 dose escalation cohorts.
    • 16 Aug 2017 Planned End Date changed from 29 Apr 2017 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top